CERS2 and cystic fibrosis: The importance of ceramides containing VLSFA, especially C22:0 and C24:0, for clearance of pulmonary infections has been shown previously in CerS2-deficient mice and in patients with cystic fibrosis, and modulation of this imbalance might be a possible drug target for managing pulmonary infections [45,46].